Retrospectively, we performed immunohistochemistry (IHC) for a panel of relatively specific biomarkers to determine their utility and clinical applicability to endoscopic biopsies: MUC2 and TFF3 for the diagnosis of BE, as well as p53, p16, cyclin D1, Ki-67, beta-catenin, and MCM2, to estimate the progression and prediction of neoplastic changes in BE. This evidence concerns the gene CDKN2A and Barrett esophagus.